RECOVER-NEURO Trial Launched to Study Long COVID Cognitive Care
Researchers have initiated a platform trial investigating new treatment interventions for cognitive decline linked to long COVID.
Updated on Oct. 5, 2026 in Alzheimer’s
Live Poll
Do you trust that federally-funded research will find effective treatments for long-term COVID symptoms?
The RECOVER-NEURO trial has launched across the United States to evaluate potential therapies for adults experiencing cognitive decline after a SARS-CoV-2 infection. This multi-center, randomized study specifically targets patients who have struggled with Post-Acute Sequelae of SARS-CoV-2 (PASC) symptoms for at least 12 weeks.
Why it matters
As many patients continue to report brain fog and reduced cognitive function long after their initial infection, this trial aims to provide evidence-based interventions for PASC-mediated cognitive issues. The platform design allows researchers to efficiently test multiple treatments to address this ongoing public health challenge.
The RECOVER-NEURO trial requires a minimum duration of 12 weeks of PASC symptoms for participant eligibility. The study is structured as a prospective, multi-arm, randomized, and partially blinded controlled trial.
The players
RECOVER-NEURO
This is a prospective multi-center platform trial dedicated to studying neurological and cognitive recovery in patients with long COVID.
NCBI
The National Center for Biotechnology Information advances science and health by providing access to biomedical and genomic information.
The details
The RECOVER-NEURO platform trial utilizes a randomized, partially blinded design to evaluate treatments for cognitive decline in outpatients who previously tested positive for SARS-CoV-2. By employing a multi-arm platform protocol, investigators can systematically assess various interventions to determine their efficacy in restoring cognitive function for those affected by long COVID.
Timeline
The official trial protocol was published on the NCBI on October 5, 2026.
The Big Picture
This study follows the established research framework set by the NIH RECOVER Initiative to address long-term health consequences of the pandemic.
Adults struggling with persistent cognitive symptoms following a COVID-19 infection may now have a pathway to participate in clinical research. This trial offers a potential route for patients to access experimental treatments for long COVID cognitive decline while contributing to broader medical knowledge.
The takeaway
Patients experiencing ongoing cognitive difficulties should consult with their healthcare providers about the potential for clinical trial enrollment. Monitoring the progression of PASC symptoms can help individuals better track their cognitive health over time.
Further reading
For additional context on research regarding cognitive health and memory decline, visit the Alzheimer’s section.
More information
View the study design and patient criteria on the RECOVER-NEURO clinical trial study portal.
Source note: This article includes information reported by The National Center for Biotechnology Information.
Live Poll
Do you trust that federally-funded research will find effective treatments for long-term COVID symptoms?
